Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Violence 'never part' of break-in plan, court told - 2Audits of Espresso Types: Which Mix Is for You?
- 37 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
- 4The most effective method to Decisively Use Open Record Rewards
- 5US FDA unveils new pathway to approve personalized therapies
- A top Marine shares his secrets to keeping fit at 50
- Overseeing Individual budgets Successfully
- Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
- Pick Your Favored kind of books
- Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing
- Starship success, a private moon landing and more: The top 10 spaceflight stories of 2025
- Insane Realities That Will Make You Reconsider How you might interpret History
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Monetary Versatility: Get ready for Life's Unforeseen Difficulties
